Heather Behanna

Achaogen's Phase 3 Shows 'Best Case Scenario'

Risks Remain For Alexion Even As Early Internal Investigation Results Seem Positive

A Primer On Endpoints: Global Blood Therapeutics

Risks Remain For Alexion Even As Early Internal Investigation Results Seem Positive

A Primer On Endpoints: Global Blood Therapeutics

What To Expect From Catabasis Pharma's Proof Of Concept Study

Wedbush Boosts Target On Sarepta Shares From $66 To $72 Amid US Launch Of Exondys 51

What To Expect From Catabasis Pharma's Proof Of Concept Study

Wedbush Boosts Target On Sarepta Shares From $66 To $72 Amid US Launch Of Exondys 51

DMD Deal With Summit Is 'Low Risk, High Reward' For Sarepta

The Search For Silver Linings In The Cloud Of Negative Novavax News